Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Show more...
FAQ
Ernexa Therapeutics 今天的股价是多少?▼
ERNAW 当前价格为 $0.04 USD,在过去 24 小时内下跌了 -10.91%。在图表上更密切关注 Ernexa Therapeutics 股票的表现。
Ernexa Therapeutics 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,Ernexa Therapeutics 的股票以代码 ERNAW 进行交易。
Ernexa Therapeutics 下一次财报日期是什么时候?▼
Ernexa Therapeutics 将于 五月 20, 2026 发布下一次财报。
Ernexa Therapeutics 有多少名员工?▼
截至四月 09, 2026,公司共有6名员工。
Ernexa Therapeutics 何时完成拆股?▼
Ernexa Therapeutics 最近没有进行任何拆股。
Ernexa Therapeutics 的总部在哪里?▼
Ernexa Therapeutics 的总部位于 US 的 Cambridge。